These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

419 related items for PubMed ID: 7370380

  • 21. Design and analysis of prostate cancer trials.
    Sylvester R.
    Acta Urol Belg; 1994 Apr; 62(1):23-9. PubMed ID: 8197926
    [Abstract] [Full Text] [Related]

  • 22. Treatment allocation for nonlinear models in clinical trials: the logistic model.
    Begg CB, Kalish LA.
    Biometrics; 1984 Jun; 40(2):409-20. PubMed ID: 6487725
    [Abstract] [Full Text] [Related]

  • 23. The clinical significance of statistical significance.
    Kane RC.
    Oncologist; 2008 Nov; 13(11):1129-33. PubMed ID: 18984874
    [Abstract] [Full Text] [Related]

  • 24. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ, Feng L.
    J Clin Oncol; 2005 Jul 01; 23(19):4450-7. PubMed ID: 15994154
    [Abstract] [Full Text] [Related]

  • 25. Crossover and self-controlled designs in clinical research.
    Louis TA, Lavori PW, Bailar JC, Polansky M.
    N Engl J Med; 1984 Jan 05; 310(1):24-31. PubMed ID: 6689736
    [Abstract] [Full Text] [Related]

  • 26. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
    Freidlin B, Simon R.
    Clin Cancer Res; 2005 Nov 01; 11(21):7872-8. PubMed ID: 16278411
    [Abstract] [Full Text] [Related]

  • 27. Application of restricted sequential design in a clinical protocol.
    Thompson EI.
    Cancer Treat Rep; 1980 Nov 01; 64(2-3):399-403. PubMed ID: 7407776
    [Abstract] [Full Text] [Related]

  • 28. [The importance of equivalence trials in showing the usefulness of treatments].
    Hermens ML, van Hout HP, Terluin B, Adèr HJ, de Haan M.
    Ned Tijdschr Geneeskd; 2003 Nov 01; 147(44):2162-6. PubMed ID: 14626832
    [Abstract] [Full Text] [Related]

  • 29. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ, Lipsky AM, Berry DA.
    Clin Trials; 2007 Nov 01; 4(1):5-14. PubMed ID: 17327241
    [Abstract] [Full Text] [Related]

  • 30. [Interim analysis in clinical trials: a methodological guide].
    Muñoz Navarro SR, Bangdiwala SI.
    Rev Med Chil; 2000 Aug 01; 128(8):935-41. PubMed ID: 11129556
    [Abstract] [Full Text] [Related]

  • 31. Designs for experiments--parallel comparisons of treatment.
    Lavori PW, Louis TA, Bailar JC, Polansky M.
    N Engl J Med; 1983 Nov 24; 309(21):1291-9. PubMed ID: 6633587
    [Abstract] [Full Text] [Related]

  • 32. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH, Lee T, Kim K, George SL.
    Stat Med; 2004 Feb 28; 23(4):561-9. PubMed ID: 14755389
    [Abstract] [Full Text] [Related]

  • 33. Sample-size calculations for trials that inform individual treatment decisions: a 'true-choice' approach.
    Girling AJ, Lilford RJ, Braunholtz DA, Gillett WR.
    Clin Trials; 2007 Feb 28; 4(1):15-24. PubMed ID: 17327242
    [Abstract] [Full Text] [Related]

  • 34. Partial likelihood analysis of within-unit variances in repeated measurement experiments.
    Chinchilli VM, Esinhart JD, Miller WG.
    Biometrics; 1995 Mar 28; 51(1):205-16. PubMed ID: 7766775
    [Abstract] [Full Text] [Related]

  • 35. [Statistical methods in the evaluation of the therapeutic efficacy--their problems and solutions].
    Tominaga S.
    Gan To Kagaku Ryoho; 1982 Nov 28; 9(11):1873-81. PubMed ID: 6764094
    [Abstract] [Full Text] [Related]

  • 36. A two stage conditional power adaptive design adjusting for treatment by covariate interaction.
    Ayanlowo AO, Redden DT.
    Contemp Clin Trials; 2008 May 28; 29(3):428-38. PubMed ID: 18053774
    [Abstract] [Full Text] [Related]

  • 37. Clinical trial designs for predictive marker validation in cancer treatment trials.
    Sargent DJ, Conley BA, Allegra C, Collette L.
    J Clin Oncol; 2005 Mar 20; 23(9):2020-7. PubMed ID: 15774793
    [Abstract] [Full Text] [Related]

  • 38. The crossover experiment for clinical trials.
    Brown BW.
    Biometrics; 1980 Mar 20; 36(1):69-79. PubMed ID: 7370374
    [Abstract] [Full Text] [Related]

  • 39. On the generalization of surgical trial results.
    van der Linden W.
    Acta Chir Scand; 1980 Mar 20; 146(4):229-34. PubMed ID: 7468047
    [Abstract] [Full Text] [Related]

  • 40. Designing for cancer clinical trials: selection of prognostic factors.
    Brown BW.
    Cancer Treat Rep; 1980 Mar 20; 64(2-3):499-502. PubMed ID: 7407790
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.